then weekly injections in the following month, and finally monthly injections after that
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
5.3 Electrocatalytic ORR Rapid expenditure of fossil fuels and massive emissions of harmful gases have compelled scientists to investigate new clean energy conversion technologies, including fuel cells, water electrolyzers, and metalair batteries
What is Glow Stack studied for in research
Systemic Anti-Inflammatory Effects BPC-157 appears to modulate inflammatory pathways broadly, potentially reducing systemic inflammation that contributes to chronic pain, slow healing, and general wellness decline